Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2

Author(s):  Horace Alexis E, Akbarian-Tefagh Jessica

Issue:  Nov/Dec 2013 - Volume 17, Number 6
View All Articles in Issue

Page(s):  446-450

Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Page 1
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Page 2
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Page 3
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Page 4
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Page 5

Download in electronic PDF format for $75

Abstract:  Adherence to antiretrovirals for pediatric patients is challenging for a variety of reasons, many of which are quite obvious. The medication’s taste and texture may contribute to a child’s resistance to following their regimen. To make the problem of compliance even more complex, there are fewer pediatric-friendly formulations available and fewer alternative options for antiretrovirals when compared to formulations and alternatives available to adults. For the sake of compliance, it is vital that parents and/or caregivers be offered innovative ways to disguise the taste of antiretrovirals for pediatric patients infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. Compounding pharmacists can play an important role in finding answers to this situation. This article provides an in-depth discussion on some of the specific flavoring and taste-masking options that are available in the effort to increase adherence in the pediatric patient population.

Related Keywords: antiretroviral agents, children, infants, human immunodeficiency virus, HIV, acquired immunodeficiency syndrome, AIDS, patient adherence, disguising taste, flavoring, aftertaste, didanosine, stavudine, tenofovir, zidovudine, abacavir, emtricitabine, lamivudine, efavirenz, nevirapine, fosamprenavir, lopinavir, ritonavir, nelfinavir, tipranavir, FLAVORx, palatability, medium chain triglycerides, MCTs

Related Categories: CANCER AND AIDS, EXCIPIENTS, PEDIATRICS, PATIENT COMPLIANCE, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2
Horace Alexis E
, Akbarian-Tefagh Jessica
Nov/Dec 2013
Pg. 446-450

Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1
Horace Alexis E
, Akbarian-Tefagh Jessica
Sep/Oct 2013
Pg. 388-391

Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome
Mathews Elizabeth
Sep/Oct 2000
Pg. 334

Featured Excipient: Flavor Enhancing Agents
Allen Loyd V Jr
Jan/Feb 2003
Pg. 48-50

Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 11: Drug Tastes: Innate, Induced, and Improved
Allen Loyd V Jr
Sep/Oct 2021
Pg. 396-400

Flavors and Flavoring
Allen Loyd V Jr
Mar/Apr 1997
Pg. 90-92

Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2
Giacoia George P
, Taylor-Zapata Perdita, Mattison Donald
May/Jun 2007
Pg. 220-225

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Compounding for the Pediatric Patient
Allen Loyd V Jr
Mar/Apr 1997
Pg. 84-86

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development—Pediatric Formulations Initiative, Part 1
Giacoia George P
, Taylor-Zapata Perdita, Mattison Donald
Jan/Feb 2007
Pg. 5-8

Compounding Challenges for Immunocompromised Patients
McElhiney Linda F
Nov/Dec 2008
Pg. 482-487

Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Polonini Hudson C
, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
Jul/Aug 2014
Pg. 332-340

Flavoring: Compounding a Treat
Kloesel Lawson G
Jan/Feb 2001
Pg. 13-16

Preparation and Characterization of a Compounded Aqueous Human Insulin Suspension
Al-Achi Antoine
, Parekh Bhavita
Nov/Dec 2004
Pg. 492-495

Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Nahata Milap C
May/Jun 2016
Pg. 247-249

Consultation for Human, Veterinary, and Compounded Medications
Moghadam Gabriella
, Forsythe Lauren Eichstadt
Mar/Apr 2017
Pg. 111-115

Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy
Kochanowska-Karamyan Anna J
Sep/Oct 2016
Pg. 367-374

Return to Top